We operate a structure-based comprehensive drug discovery platform (measured by revenue and in terms of synchrotron radiation beam time in 2017). We have many world-leading technologies and expandable business models to share the potential to increase the value of our clients' intellectual property rights. We provide world-leading structure-based drug discovery services for biotech and pharmaceutical customers around the world for innovative pre-clinical drug development. Our services cover the full range of customer needs for early drug discovery, including target protein expression and structure studies, drug screening, lead compound optimization to identification of clinical candidate compounds. Our patented core technology and our proprietary expertise enable us to effectively reduce the average time required for drug discovery, which is widely recognized by our customers. As of December 31, 2018, we have provided drug discovery services to over 370 biotech and pharmaceutical customers worldwide, covering more than 1,000 independent drug targets and delivering approximately 9,500 independent protein structures. Our mission is to be the cradle of innovative global biotech companies.